StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note released on Sunday morning. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners boosted their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

TNXP stock opened at $0.18 on Friday. The company has a 50-day simple moving average of $0.22 and a 200 day simple moving average of $2.14. The company has a market capitalization of $24.71 million, a P/E ratio of 0.00 and a beta of 2.08. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.91) by ($9.37). Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. The company had revenue of $2.21 million during the quarter, compared to the consensus estimate of $3.50 million. Sell-side analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC grew its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to its most recent filing with the SEC. The fund owned 335,373 shares of the company’s stock after acquiring an additional 242,358 shares during the period. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. 82.26% of the stock is owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.